Insulin resistance but not visceral adiposity index is associated with liver fibrosis in nondiabetic subjects with nonalcoholic fatty liver disease

Metabolic Syndrome and Related Disorders

Volumn 13, Issue 7, 2015, Pages 319-325

  Ercin, Cemal Nuri ^a   Dogru, Teoman ^a   Genc, Halil ^b   Celebi, Gurkan ^a   Aslan, Fatih ^c   Gurel, Hasan ^a   Kara, Muammer ^d   Sertoglu, Erdim ^e   Tapan, Serkan ^a   Bagci, Sait ^a   Rizzo, Manfredi ^f   Sonmez, Alper ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b Izmir Military Hospital   (Turkey)

^c IZMIR KATIP CELEBI UNIVERSITY   (Turkey)

^d GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

^e Medical Biochemistry   (Turkey)

^f UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN; INSULIN; INTERLEUKIN 6; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; ADIPOQ PROTEIN, HUMAN; AUTACOID; BIOLOGICAL MARKER; IL6 PROTEIN, HUMAN; LIPID;

ADULT; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; DIGESTIVE TRACT PARAMETERS; DISEASE ASSOCIATION; HEPATITIS; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; VISCERAL ADIPOSITY INDEX; YOUNG ADULT; BIOPSY; BLOOD; INTRAABDOMINAL FAT; LIVER; LIVER CIRRHOSIS; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; PATHOLOGY; PATHOPHYSIOLOGY; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

ADIPONECTIN; ADIPOSITY; ADULT; BIOMARKERS; BIOPSY; C-REACTIVE PROTEIN; HUMANS; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; INTERLEUKIN-6; INTRA-ABDOMINAL FAT; LIPIDS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84947427735     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2015.0018     Document Type: Article

References (37)

1. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: Old questions, and new insights. Science 2011; 332: 1519-1523
2. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-923
3. Polyzos SA, Kountouras J, Zavos C. Nonalcoholic fatty liver disease: The pathogenetic roles of insulin resistance, and adipocytokines. Curr Mol Med 2009; 9: 299-314
4. Tilg H, Moschen AR. Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab 2008; 19: 371-379
5. Arner P. Regional adiposity in man. J Endocrinol 1997; 155: 191-192
6. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89: 2548-2556
7. Bosello O, Zamboni M. Visceral obesity, and metabolic syndrome. Obes Rev 2000; 1: 47-56
8. Lefebvre AM, Laville M, Vega N, et al. Depot-specific differences in adipose tissue gene expression in lean, and obese subjects. Diabetes 1998; 47: 98-103
9. Kamada Y, Nakamura T, Funahashi T, et al. Visceral obesity, and hypoadiponectinemia are significant determinants of hepatic dysfunction: An epidemiologic study of 3827 Japanese subjects. J Clin Gastroenterol 2009; 43: 995-1000
10. Borst SE. The role of TNF-alpha in insulin resistance. Endocrine 2004; 23: 177-182
11. Tremblay AJ, Després JP, Piché ME, et al. Associations between the fatty acid content of triglyceride, visceral adipose tissue accumulation, and components of the insulin resistance syndrome. Metabolism 2004; 53: 310-317
12. Grundy SM, Cleeman JI, Merz CN, et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-239
13. Pouliot MC, Després JP, Lemieux S, et al. Waist circumference, and abdominal sagittal diameter: Best simple anthropometric indexes of abdominal visceral adipose tissue accumulation, and related cardiovascular risk in men, and women. Am J Cardiol 1994; 73: 460-468
14. Mathieu P, Pibarot P, Larose E, et al. Visceral obesity, and the heart. Int J Biochem Cell Biol 2008; 40: 821-836
15. Taksali SE, Caprio S, Dziura J, et al. High visceral, and low abdominal subcutaneous fat stores in the obese adolescent: A determinant of an adverse metabolic phenotype. Diabetes 2008; 57: 367-371
16. Kelley DE, Thaete FL, Troost F, et al. Subdivisions of subcutaneous abdominal adipose tissue, and insulin resistance. Am J Physiol Endocrinol Metab 2000; 278: E941-E948
17. Amato MC, Giordano C, Galia M, et al. Visceral adiposity index: A reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care 2010; 33: 920-922
18. Petta S, Amato MC, Di Marco V, et al. Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2012; 35: 238-247
19. Vongsuvanh R, George J, McLeod D, et al. Visceral adiposity index is not a predictor of liver histology in patients with non-alcoholic fatty liver disease. J Hepatol 2012; 57: 392-398
20. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
21. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: Insulin resistance, and beta-cell function from fasting plasma glucose, and insulin concentrations in man. Diabetologia 1985; 28: 412-419
22. American Diabetes Association. Diagnosis, and classification of diabetes mellitus. Diabetes Care 2013; 36: S67-S74
23. Kleiner DE, Brunt EM, Van Natta M, et al. Design, and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321
24. Adamczak M, Wiecek A, Funahashi T, et al. Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 2003; 16: 72-75
25. Dogru T, Sonmez A, Tasci I, et al. Plasma visfatin levels in patients with newly diagnosed, and untreated type 2 diabetes mellitus, and impaired glucose tolerance. Diabetes Res Clin Pract 2007; 76: 24-29
26. Yun JW, Cho YK, Park JH, et al. Abnormal glucose tolerance in young male patients with nonalcoholic fatty liver disease. Liver Int 2009; 29: 525-529
27. Nar A, Gedik O. The effect of metformin on leptin in obese patients with type 2 diabetes mellitus, and nonalcoholic fatty liver disease. Acta Diabetol 2009; 46: 113-118
28. Sofer E, Boaz M, Matas Z, et al. Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: A randomized, placebo-controlled trial. Metabolism, 2011; 60: 1278-1284
29. Kim HJ, Kang ES, Kim DJ, et al. Effects of rosiglitazone, and metformin on inflammatory markers, and adipokines: Decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2007; 66: 282-289
30. Díez-Rodríguez R, Ballesteros-Pomar MD, Calleja-Fernández A, et al. Insulin resistance, and metabolic syndrome are related to non-alcoholic fatty liver disease, but not visceral adiposity index, in severely obese patients. Rev Esp Enferm Dig 2014; 106: 522-528
31. Tsochatzis EA, Papatheodoridis GV, Archimandritis AJ. Adipokines in nonalcoholic steatohepatitis: From pathogenesis to implications in diagnosis, and therapy. Mediators Inflamm 2009; 2009: 831670
32. Fujii H, Kawada N. Inflammation, and fibrogenesis in steatohepatitis. J Gastroenterol 2012; 47: 215-225
33. Stojsavljević S, Gomerčić Palčić M, Virović Jukić L, et al. Adipokines, and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20: 18070-18091
34. Giby VG, Ajith TA. Role of adipokines, and peroxisome proliferator-activated receptors in nonalcoholic fatty liver disease. World J Hepatol 2014; 6: 570-579
35. Bian Z, Ma X. Liver fibrogenesis in non-alcoholic steatohepatitis. Front Physiol 2012; 3: 248
36. García-Galiano D, Sánchez-Garrido MA, Espejo I, Montero JL, et al. IL-6, and IGF-1 are independent prognostic factors of liver steatosis, and non-alcoholic steatohepatitis in morbidly obese patients. Obes Surg 2007; 17: 493-503
37. Wieckowska A, Papouchado BG, Li Z, et al. Increased hepatic, and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 2008; 103: 1372-1379